At the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, multiple myeloma expert Shaji Kumar, MD, discussed the “bonanza of treatment regimens for multiple myeloma.” Although several new treatments and combination regimens have extended survival in patients with multiple myeloma, this cancer remains an incurable chronic disease, he said.
CAR T-Cell Therapy May Not Be Needed for Select Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Value-based drug purchasing, better coordination of care delivery, and earlier institution of palliative care were among the measures to lower the cost of cancer care that were suggested during a panel discussion at the 2020 virtual National Comprehensive Cancer Network (NCCN) Oncology Policy Summit.
The COVID-19 pandemic has not only resulted in adjustments to the current Oncology Care Model (OCM), but it has led to considerations for future models, said Lara M. Strawbridge, MPH, Director, Ambulatory Payment Models, Center for Medicare and Medicaid Innovation (CMMI), Washington, DC, during the 2020 virtual National Comprehensive Cancer Network Oncology Policy Summit.
Value-based or alternative payment models have yet to deliver the cost-savings in oncology hoped for when these models were proposed, said experts at the 2020 virtual National Comprehensive Cancer Network Oncology Policy Summit during a panel discussion on best practices for value-based agreements.
FDA issues finalized guidelines for use of in vitro diagnostics in oncology drug trials and warnings on vaping; new findings report patients bear more costs when MBC treatment is not concordant with NCCN guidelines.
Orlando, FL—Maintaining patient safety and minimizing the risks for opioid misuse and abuse in the management of cancer pain require proper assessment and new strategies for pain management that include integrative interventions, according to Judith A. Paice, PhD, RN, Director, Cancer Pain Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL. She discussed this topic at the 2019 National Comprehensive Cancer Network (NCCN) Conference.
Orlando, FL—With price tags approaching $1 million or more for delivery of certain immune cell therapies, new payment models will be needed to ensure access to these therapies and to further innovations. This was a key issue addressed at a roundtable discussion at the 2019 National Comprehensive Cancer Network (NCCN) Conference. Ensuring access to chimeric antigen receptor (CAR) T-cell therapy emerged as a top area of concern.
Page 1 of 2
Results 1 - 10 of 12
Results 1 - 10 of 12